The field of myeloma has been very dynamic in the last 10 years. Indeed, in no other hematological malignancy has progress been so rapid. In Europe, five new myeloma drugs were approved in the 2‑year period during 2015–2016. This has already had a profound impact on the way we approach treatment of relapsed disease. In the near future, the results of trials evaluating some of these very new substances in first-line treatment will be available and hopefully will show a further improvement of disease control over what has already been achieved with current upfront protocols.